Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CUTTS HepC
NCT06159504Phase 1Recruiting
- Sponsor
- Médecins du Monde
- Start
- Oct 2024
- Primary completion
- Dec 2026
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of sofosbuvir and velpatasvir in hepatitis C (HCV) (2 arms), sponsored by Médecins du Monde. Primary endpoints: Feasibility of implementing care models at 3 years, Proportion of participants initiating hepatitis C treatment at 3 years and 2 more. Started Oct 2024; status: recruiting.
02
Drugs
sofosbuvirvelpatasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT06159504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06159504.